Journal Article Summary
The article examines trends in maternal exposures during pregnancy and their potential links to birth defects, using data from the National Birth Defects Prevention Study (NBDPS). This research is significant because understanding how various factors, such as obesity and medication use, change over time can help identify risks associated with major birth defects. By analyzing these trends, healthcare providers can better inform and guide expectant mothers about potential risks during pregnancy.
The study analyzed data from 11,724 mothers of infants without birth defects, collected through interviews conducted between six weeks and two years after their expected delivery dates from 1998 to 2011. Key findings revealed a significant increase in obesity among mothers, as well as increased use of selective serotonin reuptake inhibitors (SSRIs) and loratadine. Additionally, there was a rise in the use of folic acid-containing multivitamins during the periconceptional period. However, no significant trend was observed in the overall use of opioid analgesics, although some variations were noted among different racial and ethnic groups.
Limitations of the study include potential biases due to changes in study protocols and variations in participation rates over time, which could affect the reliability of the findings. Patients should be aware that self-reported data may lead to inaccuracies, and it is essential to discuss any concerns regarding medication use or other exposures during pregnancy with a healthcare professional. This conversation can help ensure that mothers receive appropriate guidance tailored to their individual circumstances and health needs.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Dawson April L., Razzaghi Hilda, Arth Annelise, Canfield Mark A., Parker Samantha E., Reefhuis Jennita. Maternal exposures in the National Birth Defects Prevention Study: time trends of selected exposures. Birth defects research. Part A, Clinical and molecular teratology 2015. DOI: 10.1002/bdra.23377. PMID: 25884728. PMCID: PMC4617636.
Featured Pill Pals Product
Loratadine 10 mg --- 300 Count Bottle --- Generic For Claritin --- Major / Rugby
Loratadine 10 mg --- 300 Count Bottle --- Generic For Claritin --- Major Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
